SUMO-1 (for small ubiquitin-related modifier) belongs to the ubiquitin (Ub) and ubiquitin-like (Ubl) protein family. SUMO conjugation occurs on specific lysine residues within protein targets, regulating pathways involved in differentiation, apoptosis, the cell cycle and responses to stress by altering protein function through changes in activity or cellular localization or by protecting substrates from ubiquitination 1,2 . Ub/Ubl conjugation occurs in sequential steps and requires the concerted action of E2 conjugating proteins and E3 ligases 1,2 . In addition to being a SUMO E3, the nucleoporin Nup358/RanBP2 localizes SUMOconjugated RanGAP1 to the cytoplasmic face of the nuclear pore complex by means of interactions in a complex that also includes Ubc9, the SUMO E2 conjugating protein [3] [4] [5] [6] . Here we describe the 3.0-Å crystal structure of a four-protein complex of Ubc9, a Nup358/RanBP2 E3 ligase domain (IR1-M) and SUMO-1 conjugated to the carboxy-terminal domain of RanGAP1. Structural insights, combined with biochemical and kinetic data obtained with additional substrates, support a model in which Nup358/ RanBP2 acts as an E3 by binding both SUMO and Ubc9 to position the SUMO-E2-thioester in an optimal orientation to enhance conjugation.
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Ub/Ubls are activated by E1 and transferred to E2 to form E2-Ub/ Ubl-thioesters. Although competent for Ub/Ubl ligation to lysine 1-amino groups, E2s generally require E3 ligases to recognize substrate lysine residues specifically. Most E3s belong to either RING or HECT families, and whereas RING E3s recruit substrate and bind the E2-Ub/Ubl through a zinc domain to promote conjugation to lysine residues 7 , HECT E3s recruit E2-Ub/Ubl to generate E3-Ub/Ublthioesters for conjugation 8 . The SUMO E2 can directly bind the consensus sequence W-K-X-D/E where W is a hydrophobic amino acid, K is the substrate lysine, X is any amino acid and D or E is acidic 9 , although several SUMO E3s facilitate conjugation in vivo and in vitro; they include RING-type E3s 10, 11 , Nup358/RanBP2 (ref. 12) and Pc2 (ref. 13 ). Nup358/RanBP2 and Pc2 seem unrelated to either RING or HECT E3 ligases.
One of the first discovered functions for SUMO-1 was its role in nucleocytoplasmic trafficking [3] [4] [5] . SUMO conjugation localizes RanGAP1 to the nuclear pore complex (NPC) in a complex that includes the SUMO E2 Ubc9 and Nup358/RanBP2, a multi-domain 3,224-residue nucleoporin that also interacts with Ran and other nuclear transport factors [3] [4] [5] [6] 14, 15 . The SUMO-RanGAP1-Ubc9-Nup358/RanBP2 complex does not dissociate on entry into mitosis and NPC disassembly, but redistributes to kinetochores and contributes to the stability of kinetochore-microtubule interactions 16 . A roughly 30-kDa Nup358/RanBP2 fragment named IR1-M-IR2 binds Ubc9 and promotes SUMO E3 activity in vitro and in vivo 12, [17] [18] [19] , although domains flanking IR1-M-IR2 also contribute to SUMO-RanGAP1 interactions 6 . IR1-M-IR2 was parsed into three elements: IR1 (residues 2,633-2,685), M (residues 2,686-2,710) and IR2 (residues 2,711-2,761). IR1 and IR2 were named for two internal sequence repeats. IR1-M-IR2, IR1-M and M-IR2 all promote SUMO-1 conjugation in vitro 18, 19 . To determine the molecular details of this system, SUMO-1 was conjugated to RanGAP1, combined with Ubc9 and Nup358/RanBP2, purified by gel filtration, and crystallized. The model containing SUMO-1 (residues 20-97), RanGAP1 (residues 432-587), Ubc9 (residues 2-157) and Nup358/RanBP2 (residues 2,631-2,693) was refined to 3.0 Å (R ¼ 24.7, R free ¼ 29.0; Table 1, Supplementary  Table 1 and Supplementary Methods). The structure reveals Ubc9 as the central component of the quaternary complex, contacting SUMO, RanGAP1 and Nup358/RanBP2 (Fig. 1) . SUMO contacts Ubc9 and Nup358/RanBP2, but contacts RanGAP1 only through the covalent bond between SUMO Gly 97 and Lys 524. Nup358/RanBP2 contacts SUMO and Ubc9 but does not contact RanGAP1.
The human SUMO-1-RanGAP1-Ubc9 complex is similar to our previously described complex between mouse RanGAP1 and human Ubc9 in that most interactions to the RanGAP1 W-K-X-D/E SUMO motif (L-K-S-E) are preserved 9 21 . Residues in the interface between SUMO-1 and Ubc9 are conserved among SUMO and Ubc9 family members. The small interface between SUMO and Ubc9 is consistent with the complexes being primed to dissociate after conjugation. It is also consistent with the specificities of Ubc9-SUMO being achieved by the SUMO E1 activating enzyme, which brings SUMO and Ubc9 together to form the thioester adduct 21 . Several observations indicate that the Ub/Ubl-E2-thioester might adopt a similar configuration to that observed in our complex before conjugation. First, NMR chemical shift perturbations observed for a 2 ). We previously indicated that E2s might coordinate the lysine near the labile E2-Ub/Ubl-thioester to promote chemistry 9 . The absence of other E2 catalytic residues led to recent studies that implicated the conserved E2 His-Pro-Asn amino acid motif (HPN) in catalysis, namely that Asn Nd contributes to formation of an oxyanion hole that stabilizes the transition state 23 . Our structure is consistent with this proposal in that as Asn 85 Nd moves away from the Ubc9 main chain it approaches the C-terminal Gly 97 carbonyl oxygen, although definitive evidence for the catalytic role of Asn 85 is precluded by the resolution limits of our structure (3.0 Å ) and because our complex includes a conjugated product rather than a E2-SUMO-thioester substrate complex.
LETTERS
Nup358/RanBP2 IR1-M adopts a non-globular and extended structure in the complex (Fig. 3 ). IR1-M elements were divided into motifs I-V based on interactions in the complex (Fig. 3a) . Motif I forms an antiparallel b-strand with SUMO b-strand 2. In addition to main-chain contacts, motif I includes two acidic and five hydrophobic residues that contribute ionic and van der Waals contacts to SUMO-1 residues, respectively (Fig. 3c ). The C-terminal end of IR1 a-helix A contacts the Ubc9 amino-terminal helix in addition to Pro 69, Pro 105 and Ala 106. Ubc9 Arg 8 bridges four main-chain carbonyl oxygen atoms, two from Ubc9 and two from Nup358/ RanBP2 (Fig. 3d) . Motif II forms a coil that packs hydrophobic residues into the interface formed by the Ubc9 N-terminal helix and residues between b1 and b2 of SUMO-1 (Fig. 3d) . Motif III acidic residues bridge the Ubc9 N-terminal helix and contact Ubc9 Arg 13, Arg 17 and Lys 30 (Fig. 3e) . IR1 then forms a-helix B, packing motif IV hydrophobic residues onto Ubc9 b1-b3 (Fig. 3f ) before contacting Ubc9 b2, b3 and Phe 22 through Leu 2688-Tyr 2689-Leu 2690 in motif V (Fig. 3g) . The extended structure buries 1,460 Å 2 in the SUMO interface and 830 Å 2 in the Ubc9 interface. On the basis of our structure, new sequence alignments between IR1 and IR2 were used to generate IR1*, IR2* and IR1-M-IR2* (Fig. 3a) .
RanGAP1 is easily conjugated and interacts strongly with Ubc9 through surfaces adjacent to the conjugation site 9 . It therefore remains unclear whether Nup358/RanBP2 E3 activity is required for RanGAP1 SUMO conjugation, or whether it is required merely to maintain a stable complex at the nuclear pore. The stable interactions observed between RanGAP1 and E2 and between E3, SUMO and E2, and the covalent interaction in RanGAP1-SUMO, indicated that our structure might represent a trapped product complex. To test this, conjugation assays with RanGAP1 under multiple-turnover conditions with and without Nup358/RanBP2 IR1* showed, in contrast to other substrates 12, 18, 19 , that IR1* inhibited SUMO conjugation. SUMO-RanGAP1 accumulated to near-stoichiometric ratios of product, E2 and E3 (Fig. 4a) . The addition of SUMO-RanGAP1 also inhibited SUMO conjugation to p53 in an IR1*-dependent manner (Fig. 4b) . Again, stoichiometric ratios of SUMO-1-Ran-GAP1 to E2 seemed sufficient to sequester E2 and prevent further p53 conjugation. Partial disruption of the stable interface between RanGAP1 and Ubc9 alleviated IR1*-dependent inhibition in multiple-turnover assays and rendered RanGAP1 a substrate for Nup358/RanBP2 E3 activity under single-turnover conditions (Supplementary Fig. 1) .
To assess the importance of contacts between Nup358/RanBP2, SUMO and E2, assays were conducted at near-saturating substrate concentrations under multiple-turnover and single-turnover conditions to quantify rate velocities by using E3 constructs and substrates that included the p53 tetramerization domain, IkBa, and a peptide containing a SUMO consensus motif ( Fig. 3a; see Methods). IR1* and IR1-M-IR2* enhanced conjugation rates up to 80-fold in multiple-turnover assays (Fig. 4c-e) , and IR2* enhanced conjugation 4-16-fold. IR1T included only motifs I and II but catalysed E3 activity at a rate similar to that of IR2*, indicating that motifs III-V might be somewhat dispensable for activity. Deleting motif I (TIR1 and TIR2) from either IR1 or IR2 resulted in almost no E3 activity. Similar rate enhancements were observed under singleturnover conditions using isolated E2-SUMO-thioester (see Methods) ( Fig. 4f-h) .
Consistent with observations for motif I in our structure was the recent use of NMR to identify Nup358/RanBP2 IR1 amino acids (motif I) that interact with SUMO; although E3 activity was not assessed, several mutations within motif I diminished binding to SUMO-1-RanGAP1 (Fig. 3c ) 24 . SUMO-1 interactions with Nup358/ RanBP2 motif I might be recapitulated by other proteins that interact non-covalently with SUMO 24 and Smt3 (ref. 25) . Mutational analysis revealed the importance of Nup358/RanBP2 motif II residues Leu 2651, Leu 2653, Phe 2657 and Phe 2658 in Ubc9 binding and E3 activity 18 , residues that contact Ubc9 in our structure (Fig. 3a, d ). This and another study identified Ubc9 mutations that partly diminished both E3 activity and binding to Nup358/RanBP2 (refs 18, 19) . Most detrimental Ubc9 mutations face Nup358/ RanBP2 motifs IV and V in our structure. The latter study also indicated a possible mechanism for SUMO paralogue selection by various Nup358/RanBP2 IR1-M-IR2 domains 19 . To confirm that SUMO-2/SUMO-3-E2 is activated in an analogous manner to that proposed for SUMO-1-E2, we assayed SUMO-2 and SUMO-3 under single-turnover conditions. These data revealed rate enhancements for IR1-M-IR2* and IR1*, and a strict dependence on motif I for activity ( Supplementary Fig. 2) .
If Nup358/RanBP2 binds E2-SUMO-thioester in a manner similar to that observed in our complex, E3 activity is achieved independently of contacts to the substrate or E2's active site. So how does Nup358/RanBP2 work? Conjugation rates could be increased by an allosteric mechanism that alters the E2 active site indirectly to enhance catalysis 18 , possibly activating the thioester, leaving group, or alters E1's ability to charge E2. However, thioester reactivity was not altered when E2-SUMO-thioester was incubated with 0, 1 or 10 mM dithiothreitol (DTT) with or without E3. Differences were also not observed in E1-mediated E2-SUMO-thioester formation with or without E3, although 10:1 or 100:1 E3:E2 molar ratios inhibited the formation of E1-SUMO and E2-SUMO-thioester.
The importance of motif I and motif II for IR1* and IR2* E3 activity and the small interface observed between Ubc9 and SUMO indicated a possible model in which Nup358/RanBP2 catalyses E3 activity by tethering SUMO and Ubc9 together to reduce conformational flexibility, to prevent non-productive E2-SUMO conformations, and to align the complex and thioester for Ubl transfer. If this is true, and contrary to previous observations 12, 18, 19 or the lack of substrate contacts, both substrate binding and catalysis should be affected. To test this, initial rate velocities were calculated over various p53 concentrations under single-turnover conditions with and without IR1*. The kinetic data fitted well to an equation from which K d and k 2 (k cat ) were derived ( Fig. 4i ; see Methods). In the absence of IR1*, K d and k 2 for p53 conjugation were 23.1^4.8 mM and 4.27^0.37 pM s 21 , respectively (^s.d.). In the presence of IR1*, K d and k 2 were 3.04^0.47 mM and 104.7^4.3 pM s 21 , respectively. Thus, both K d and k 2 were affected by IR1* to increase
SUMO-conjugated RanGAP1, in stoichiometric quantities, sequesters Ubc9 and substantially diminishes its ability to promote conjugation of exogenous substrate in the presence of Nup358/ RanBP2 (see above). Because IR1-M contacted only Ubc9 and SUMO in our complex, we predicted that an additional equivalent of Ubc9-SUMO-thioester should compete with a preformed E2-E3-SUMO-RanGAP1 complex for IR1-M interaction. In fact, singleturnover assays indicated that IR1-M dissociated from the complex, enhancing Ubc9-SUMO-1-thioester conjugation 11-fold (Fig 4f-h) . These data indicate that although Nup358/RanBP2 might form a stable complex with SUMO-RanGAP1, it might still be available to promote E3 activity by binding additional E2-SUMO-thioesters, a model that has cellular implications for Nup358/RanBP2 E3 activity if E2-SUMO concentrations are sufficient to compete for Nup358/ RanBP2 at the NPC.
The SUMO-RanGAP1-Ubc9-Nup358/RanBP2 structure provides data for several interactions that are crucial for E3-assisted E2 conjugation, including the model that Nup358/RanBP2 enhances conjugation by coordinating the E2-SUMO-thioester optimally for substrate binding and catalysis. Comparison between Nup358/ RanBP2-Ubc9-SUMO-RanGAP1 and two other E2-E3 structures 26, 27 , E6AP-UbcH7 and c-Cbl-UbcH7, reveal distinct but overlapping E2 surfaces used in each complex. By aligning respective E2s, SUMO was placed into the other E2-E3 complexes. The RING domain and other E3 surfaces are well positioned to recognize Ub within the modelled E2-Ub-thioester complexes ( Supplementary  Fig. 3 ).
The indirect mechanism used by Nup358/RanBP2 to enhance SUMO conjugation might shed some light on 'allosteric' activation observed in other Ub/Ubl pathways such as the RING-finger and Nedd8-induced activation of the Cullin SCF complexes 7 , Apc11 induced activation of the APC complex 27 , all of which might coordinate E2-Ub in a complex similar to that observed in our structure. Mechanisms proposed here might also provide insights, although less clear ones, into activities that promote E2-Ub/Ublthioester activation during polyubiquitin chain formation 28 .
METHODS
Cloning, expression and protein purification. Preparation of human E1
(Sae1/Sae2), E2 (Ubc9), SUMO-1 (1-97), SUMO-1 (18-97), the C-terminal p53 tetramerization domain and IkBa have been described previously 9, 21 . Human RanGAP1 (residues 419-587) and Nup558/RanBP2 constructs (IR1*, IR1-M, IR1-M-IR2*, TIR1, IR1T, IR2* and TIR2; see Fig. 3a ) were amplified by polymerase chain reaction and cloned into a Smt3 vector 9, 21 . Constructs were confirmed by DNA sequencing. E3 constructs included IR1-M-IR2* (residues 2,631-2,771), IR1* (residues 2,631-2,695), IR2* (residues 2,709-2,771), TIR1 (residues 2,640-2,695), TIR2 (residues 2,718-2,771) and IR1T (residues 2,631-2,670). The synthetic p53-derived peptide includes residues 380-393 (HKKLMFKTEGPDSD). Biochemical assays used proteins that were concentrated in buffer containing 350 mM NaCl, 20 mM Tris-HCl pH 8.0 and 1 mM DTT, flash-frozen in liquid nitrogen and stored at 280 8C. Cultures were fermented at 37 8C to a D 600 of 3, induced with 0.75 mM isopropyl b-Dthiogalactoside for 4-6 h at 30 8C, harvested and suspended in 50 mM Tris-HCl pH 8.0, 20% w/v sucrose, 350 mM NaCl, 20 mM imidazole, 0.1% IGEPAL, 1 mM phenylmethylsulphonyl fluoride, 1 mM 2-mercaptoethanol, 10 mg ml 21 DNase before sonication and the removal of insoluble material by centrifugation. Proteins were purified by metal-affinity chromatography (Qiagen), gel filtration (Superdex75 or Superdex200; Pharmacia), and ion exchange (MonoQ and MonoS). SUMO-RanGAP1 was prepared and combined with Ubc9 and IR1-M (residues 2,631-2,711), purified by gel filtration (Superdex200), and concentrated to 10 mg ml 21 in 50 mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM DTT, frozen in liquid nitrogen and stored at 280 8C.
Crystallographic analysis. Crystals were obtained at 18 8C by hanging-drop vapour diffusion against a well solution containing 18% w/v PEG4000, 0.1 M sodium citrate pH 5.0, 0.2 M ammonium acetate and transferred to crystallization solutions containing 12% ethylene glycol before cryoprotection. Data were processed and the structure solved by molecular replacement using human RanGAP1-Ubc9 coordinates to phase the complex at 4 Å . SUMO-1 was modelled on the basis of previous structures 21 . Nup358/RanBP2 was modelled into electron density that became apparent after refinement of SUMO-Ran-GAP1-Ubc9. Nup358/RanBP2 residues 2,663, 2,665, 2,666, 2,669 and 2,670, not clearly present in the electron density, were modelled without side chains. Refinement and data statistics are provided in the text and Supplementary Table 1 .
Biochemical assays. Assays were conducted in triplicate. Samples were removed at specified times, denatured in non-reducing SDS-PAGE buffer containing 4 M urea (single turnover) or reducing SDS-PAGE buffer (multiple turnover), analysed by SDS-PAGE and western blotting with a polyclonal rabbit antibody against SUMO-1 (Boston Biochem), and developed by enhanced chemiluminescence with ECL-Plus (Amersham). Data were imaged with a Fujifilm LAS-3000 Imager and quantified with Image Gauge v4.0 (FujiFilm).
For the multiple-turnover reaction, reactions were performed at 37 8C in 150 nM E1, 100 nM Ubc9 (E2), 10 mM SUMO-1 (1-97), 5 mM MgCl 2 , 0.1% Tween 20, 20 mM Hepes pH 7.5, 50 mM NaCl, 1 mM DTT, and the indicated Nup358/RanBP2 constructs (200 nM) using 8 mM p53 tetramerization domain (p53), 4 mM IkBa or 500 mM p53 peptide as substrate. RanGAP1 conjugation was assessed in the presence or absence of IR1* (200 nM). Inhibition of p53 conjugation by RanGAP-SUMO was assessed with and without IR1* (200 nM) in reactions containing RanGAP1-SUMO-1 at 0, 0.04, 0.08, 0.12, 0.14, 0.16 or 0.32 mM.
For the single-turnover reaction, E2-SUMO-thioester was formed at 37 8C in non-reducing buffer containing 100 nM E1, 1 mM Ubc9 (E2), 5 mM MgCl 2 , 0.1% Tween 20, 20 mM Hepes pH 7.5, 50 mM NaCl, 1 mM mature SUMO-1 (1-97) and 1 mM ATP, and stopped after 10 min by tenfold dilution at 4 8C in buffer containing 5 mM EDTA. Diluted reactions contained 10 nM E1, 100 nM Ubc9 (E2), 100 nM mature SUMO-1, 0.5 mM MgCl 2 , 5 mM EDTA, 0.1% Tween 20, 20 mM Hepes pH 7.5, 50 mM NaCl, either 8 mM p53 or 4 mM IkBa, and the indicated Nup358/RanBP2 elements at 100 nM. Reactions also included p53 in the presence of 100 nM RanGAP1-Ubc9-SUMO-Nup358/RanBP2 (IR1-M). Data in Supplementary Fig. 2 were generated under single-turnover conditions by replacing SUMO-1 with SUMO-2 (1-93) or SUMO-3 (1-92). Rate constants were calculated for p53 by measuring rate velocities under single-turnover conditions with and without IR1* (100 nM), using 0, 0.08, 0.4, 0. 
